$2.85
+0.44 (+18.26%)
Open$2.48
Previous Close$2.41
Day High$2.88
Day Low$2.44
52W High$7.80
52W Low$1.01
Volume—
Avg Volume945.1K
Market Cap197.13M
P/E Ratio—
EPS$-1.75
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,267.4% upside
Current
$2.85
$2.85
Target
$38.97
$38.97
$29.17
$38.97 avg
$44.78
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 77.00M | 76.19M | 65.35M |
| Net Income | -1,399,615 | -1,371,226 | -1,459,846 |
| Profit Margin | -1.8% | -1.8% | -2.2% |
| EBITDA | -1,495,155 | -1,465,448 | -1,363,438 |
| Free Cash Flow | -1,111,108 | -1,336,142 | -1,081,347 |
| Rev Growth | +16.0% | +7.1% | -1.4% |
| Debt/Equity | 0.13 | 0.12 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |